CD8A and neoplasm: While our data cannot answer this question definitively, it still provides some insights: when blocking new influx from the lymph node, combination therapy led to a better response compared to anti-PD-L1 alone, suggesting that in situ proliferation of CD8 T cells with stem-like phenotype may at least in part be driving TCR diversification, CD8 T effector cell rejuvenation, increase in IFNγ expression and tumor rejection.